NCT07020221: An ongoing trial by Verastem, Inc.
This trial is ongoing. It must report results 3 years, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07020221 |
|---|---|
| Title | A Phase 1/2a, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 24, 2025 |
| Completion date | Sept. 30, 2028 |
| Required reporting date | Sept. 30, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |